Using calprotectin levels to differentiate spondyloarthritis from other conditions
Study of the Interest of Serum Calprotectin Determination in the Diagnosis of Spondyloarthritis and to Diferenciate With Fibromyalgia
This study is testing if measuring calprotectin levels in stool can help tell the difference between spondyloarthritis and other conditions like fibromyalgia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 190 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice) |
| Trial ID | NCT05555433 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the potential of fecal calprotectin as a biomarker for distinguishing spondyloarthritis from fibromyalgia and other conditions. It will analyze calprotectin levels in patients with active and low-activity spondyloarthritis, fibromyalgia, and healthy controls. The study seeks to clarify the relationship between calprotectin levels and disease activity in spondyloarthritis, building on previous research that has shown mixed results. By assessing these biomarkers, the study hopes to provide insights into disease management and diagnosis.
Who should consider this trial
Good fit: Ideal candidates include patients with active or low-activity spondyloarthritis, fibromyalgia without inflammatory rheumatism, or healthy individuals.
Not a fit: Patients who are minors, not affiliated with the social security system, or under guardianship will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy for spondyloarthritis, helping to differentiate it from similar conditions.
How similar studies have performed: While some studies have shown potential for calprotectin as a marker in related conditions, this specific approach in spondyloarthritis remains novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients in the active line of the rheumatology department with one of the following criteria: active spondyloarthritis (BASDAI \>4), or spondyloarthritis in low activity (BASDAI\<4), or fibromyalgia without associated inflammatory rheumatism, or healthy subjects (without inflammatory rheumatism and without fibromyalgia. Patients who have not objected to the use of their samples Exclusion Criteria: Minor patient Subject not affiliated to the social security system Subject deprived of liberty Patient under guardianship or curatorship
Where this trial is running
Nice
- Nice University Hospital — Nice, France (Recruiting)
Study contacts
- Study coordinator: Christian ROUX, PUPH
- Email: roux.c2@chu-nice.fr
- Phone: 33492035491
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.